RecipientAmountDeal/Technology HighlightLead InvestorsDeal TypeCountry
Nektar$3,600 millionTo evaluate the full-potential of NKTR-214 plus Opdivo (nivolumab) across numerous tumors, based on promising early data from ongoing Phase 1/2 PIVOT clinical studyBristol-Myers SquibbCollaborationUnited States
Sangamo Therapeutics$3,150 millionTo Develop Next-Generation Engineered Cell Therapies for the Treatment of CancerKite (Gilead Company)CollaborationUnited States
Flatiron Health$1,900 millionTo accelerate industry-wide development and delivery of breakthrough medicines for patients with cancerRocheDefinitive AgreementUnited States
Voyager Therapeutics$1,200 millionTo Develop Potential New Treatments for Alzheimer’s Disease and Other Tau-Related Neurodegenerative DiseasesAbbVieCollaboration United States
Pieris Pharmaceuticals$1,200 millionTo Evaluate Novel Bispecific Immuno-Oncology Agents that Combine Pieris’ Anticalin Technology with Select Seattle Genetics Cancer-Targeted AntibodiesSeattle GeneticsCollaborationUnited States
CJ HealthCare$1,200 millionTo develop new drugs and expand sales networks and continue the manufacturing and development of existing drugsKorea KolmarAcquisitionRepublic of Korea
Theravance Biopharma Ireland Limited$1,000 millionBoth Jointly Develop and Commercialize TD-1473, a Novel, Potent, Orally Administered and Intestinally Restricted pan-Janus Kinase (JAK) InhibitorJanssen (Johnson & Johnson )CollaborationIreland
Wave Life Sciences Ltd$1,000 millionTo receive option to co-develop and co-commercialize investigational therapies in HD, ALS, FTD and SCA3 under a global 50:50 profit-split & receive right to license additional preclinical CNS programsTakeda Pharmaceutical CompanyCollaboration United States
MPI Research$800 millionTo enhance Charles River’s position as a leading global early-stage CRO by strengthening its ability to partner with clients across the drug discovery and development continuumCharles RiverAcquisitionUnited States
POXEL SA $600 millionFor Development and Commercialization of Imeglimin in the U.S., Europe, and Additional Countries WorldwideRoivant SciencesAgreementFrance
Moderna Therapeutics$500 millionThe funding will help drive the company’s continued execution of its rapidly growing pipeline of 19 development candidates – including 10 programs in clinical trialsAbu Dhabi Investment Authority (ADIA), BB Biotech AG, Julius Baer, Singapore-based EDBI and Sequoia Capital ChinaEquity FinancingUnited States
Viralytics $394 millionProposed Acquisition of Viralytics Would Add Investigational Oncolytic Immunotherapy, CAVATAK ® , Supporting Merck’s Strategy to Broaden Its Pipeline with the Best Scientific AssetsMerckDefinitive AgreementAustralia
Ionis Pharmaceuticals$330 millionIonis Licences New Antisense Drug for Kidney Disease to AstraZenecaAstraZenecaCollaborationUnited States
GNC Holdings$300 millionHayao will also form a JV with GNC to make and distribute GNC supplements in ChinaHarbin PharmaInvestment United States
TandemLife$300 millionCompany will add advanced cardiopulmonary temporary support solutions to its portfolioLivaNovaAcquisition United States
TetraGenetics$300 millionTetraGenetics expertise and ideally suited to the capabilities of the TetraExpress™ platform technology. These programs build on TetraGenetics’ prior successes using the platform for the discovery of drug candidates targeting membrane proteinsUndisclosedCollaboration United States
Viela Bio$250 million To create stand-alone company for early-stage inflammation and autoimmunity biologicsAstraZeneca, Boyu Capital, 6 Dimensions Capital, and Hillhouse CapitalFundingUnited States
Celularity$250 millionDeliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional RegenerationCelgeneFundingUnited States
Novo Nordisk$165 millionTo invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance.Novo Nordisk FoundationInvestment Denmark
ImmunoQure$164 millionPartnership for the development of an Interferon alpha human autoantibodyServierPartnership Germany
Rani Therapeutics$142 millionRani raises investment for manufacturing of a pill that replaces injectionsGeneScience PharmaceuticalsFundingUnited States
Polyphor$129 millionTo Develop and Commercialize Clinical Stage Candidate for Cystic Fibrosis and Other Pulmonary Diseases for POL6014Santhera PharmaceuticalsLicensing Agreement Switzerland
PROCEPT BioRobotics$118 millionTreatment of Benign Prostatic HyperplasiaViking Global Investors LP & CPMG, IncFundingUnited States
Arcus Biosciences$107 millionThe proceeds from this financing will be used for the advancement of Arcus’s clinical programs for AB928, a first-in-class dual adenosine receptor antagonist, and AB122, a PD-1 antibodyGV (Google Ventures)Series C Financing United States
Oxford BioMedica$105 million To use OXB’s LentiVector Enabled technology and access to its industrial-scale manufacturing technologyBioverativCollaboration & License AgreementUnited Kingdom
Avid Bioservices, Inc$103 millionAsset Assignment and Purchase Agreement for Avid's PS-Targeting Program Including BavituximabOncologiePurchase AgreementUnited States
Universal Cells$102.5 millionTo fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areasAstellas Pharma Inc.Acquisition United States
Generation Bio$100 millionTo Advance Genewavetm Platform For Re-Dosable Gene TherapyFidelity Management & Research Company, with InvusInvestment United States
BD (Becton, Dickinson and Company)$100 millionFor Purchase of Divestment Assets, The assets acquired are soft tissue core needle biopsy products sold under the trade names of Achieve™ Programmable Automatic Biopsy System, Temno™ Biopsy System, Tru-Cut™ Biopsy Needles as well as Aspira® Pleural Effusion Drainage Kits, and the Aspira® Peritoneal Drainage SystemMerit Medical Systems IncInvestment United States
Elastagen Pty Ltd$95 millionTo Access Next Generation Injectable Portfolio & Clinical stage tropoelastin platform with potential applications in aesthetics, scar remodeling and surgical wound repairAllergan plcDefinitive AgreementAustralia
Surmodics$92 millionCompanies to collaborate on product development, clinical trials and regulatory activities to obtain approval in U.S. and E.U.ABBOTTAgreement United States
AVROBIO, Inc$60 millionTo Advance Gene Therapy Pipeline for Lysosomal Storage Disorders and Apply Lentiviral Platform to Other Genetic DiseasesSyndicate, Atlas VentureSeries B Financing United States
Inscripta$55.5 millionTo accelerate development and commercialization of gene-editing tools — including enzymes, reagents, instrumentation, and softwareMerieux Developpement and Paladin Capital GroupSeries C Financing France
Senti Biosciences$53 millionTo Build the Future of Gene and Cell-Based TherapiesNew Enterprise Associates (NEA)Series A FinancingUnited States
ORIC Pharmaceuticals$50 millionProceeds will support advancement of ORIC-101 against treatment-resistant solid tumors and continued progress on mechanisms of resistance in cancerFidelity Management & Research Company, Trinitas Capital, Taiho Ventures, and NS Investment etcSeries C Financing United States
Quentis Therapeutics$48 millionRole of small-molecule inhibitor of IRE1 alpha, a key ER stress pathway in Cancer TreatmentAbbVie VenturesSeries A FinancingUnited States
Tetraphase Pharmaceuticals, Inc.$42.5 millionTetraphase and Everest will establish a joint steering committee to review and oversee all of Everest’s development and commercialization plansEverest Medicines LimitedLicensing Agreement United States
Ferring Biotech Centre$31.9 million Ferring expands its capabilities in biologics through a new biotech centre & In addition to new biologics in reproductive medicine and women’s health, fertility treatment Rekovelle® (follitropin delta) will also be manufactured at the new centreFerring PharmaceuticalsInvestment Switzerland
IQGEN Holdings LLC$25 millionThe Vantage fund aims to invest in technology-driven healthcare companies in India and other Asian nations, founder and managing partnerVenture CapitalInvestment India
Revance Therapeutics$25 millionTo Bring a Biosimilar to the Market for the development and commercialization of a proposed biosimilar to BOTOX® (onabotulinumtoxinA)Mylan N.VCollaboration & License AgreementUnited States
Neurona Therapeutics$23.5 millionTransplantation of selected neurons to treat intractable neurological diseasesThe Column GroupSeries A financingUnited States
UCB (Syndesi Therapeutics)$20.9 millionTo develop a series of molecules that modulate the protein SV2A, which is involved in synaptic transmissionV-Bio Ventures and the venture arms of Novo Nordisk & Fountain Healthcare together with Johnson & Johnson Innovation - JJDC, IncPartnership Belgium
Exelixis, Inc.$20 millionSubmission of Regulatory Filing for Esaxerenone (CS-3150) in JapanDaiichi Sankyo Company, LimitedCollaboration AgreementUnited States
ABAC Therapeutics$19.69 millionTo Develop Therapeutic Solutions to Fight Antibiotic-Resistant BacteriaPontifaxSeries A FinancingSpain
Prokarium$10 millionFor clinical development of revolutionary thermostable vaccinesRiyadh Valley Company (RVC) & Saudi, Swedish and Korean investorsInvestment United Kingdom
SMART Medical Systems Ltd$8 millionSMART's present financing will be used primarily to commercialize its G-EYE® productSignet Healthcare Partners, a NY-based healthcareSeries B FinancingIsrael
Avadel Pharmaceuticals$8 millionUnder the terms of the licensing and development agreement, Avadel will develop and provide Cerecor with four stable product formulations utilizing its LiquiTime™ and Micropump® platforms.Cerecor, Inc. (CERC)Definitive AgreementRepublic of Ireland
Aakar Innovations, Saathi Eco Innovations etc (India) $7.9 millionSupport of women’s empowerment, sexual and reproductive health and rights, water and sanitation, and global mental health in IndiaGovt.of Canada through Global Affairs CanadaInvestment India
Synergy Pharmaceuticals$5.0 millionAcquires Exclusive Canadian Rights to FDA-Approved TRULANCE®Cipher PharmaceuticalsAcquisition United States
Randob Labs$4.25 millionTo divest the brand BalmexMoberg Pharma ABAgreement United States
Solaris Nutraceuticals$1.95 millionBuilding the largest medical cannabis greenhouse southern hemisphere facilityFederal Department of Innovation, Industry & ScienceFederal GrantAustralia
Amarantus$1.5 millionPhase 2b Eltoprazine program for Parkinson's disease levodopa-induced dyskinesia (PD-LID) and Cutanogen Corporation's pending pivotal trial in Pediatric Severe BurnsDominick & Dickerman LLCDefinitive AgreementUnited States
SCIEXUndisclosedDevised an isotopic methodology in which all biological molecules are uniformly and randomly labeled to create informative isotopic patterns that are readily discriminated from artifactsIROA Technologies LLCCo-Marketing Agreement United States
Massachusetts General HospitalUndisclosedProgression of neurofibrillary tangles (NFTs) and Parkinson's Disease tau proteinCerveau Technologies, IncResearch Agreement United States
Preora HealthcareUndisclosedTo Bring Novel Intracellular Visualization Technology to Cancer Diagnostic MarketPlanet InnovationCollaborationUnited States
Evinance Innovation, IncUndisclosedThis acquisition expands the capabilities of Varian's 360 Oncology™ care management platform by tightly integrating clinical workflow, decision support, and adherence tracking based on leading cancer care guidelinesVarianAcquisitionCanada
Bridgemedica, LLCUndisclosedTo further diversify portfolio and expand into markets that we believe have strong growth potentialNN, IncAcquisitionUnited States
ATUMUndisclosedTo Accelerate Drug Discovery ATUM licenses Company’s Leap-In Transposase® TechnologyJust BiotherapeuticsPatent Licensing Agreement United States
Melinta TherapeuticsUndisclosedEurofarma Laboratórios is Melinta’s commercialization and distribution partner for all countries in South and Central America and the Caribbean, including Argentina. The proposed indication for delafloxacin in Argentina is for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI).Eurofarma LaboratóriosCommercialization AgreementBrazil
OrthotaxyUndisclosedTo Develop Next-Generation Robotic-Assisted Surgery Platform in OrthopaedicsJohnson & Johnson Medical DevicesAcquisitionFrance
Pure Applied SciencesUndisclosedTo acquire Pure Applied Sciences and its brand PureOrganix, a line of organic and pure cannabis oils and related accessoriesCannabis Strategic Ventures, InAcquisitionUnited States
ABAC TherapeuticsUndisclosedABAC develops new targeted antibiotics for patients with severe infectionsDebiopharm Group ,Debiopharm Innovation FundAcquisition Spain
Apex Resource TechnologiesUndisclosedMedical Plastics Leader Enhances Specialty Products Portfolio & Design Engineering Through AcquisitionSpectrum Plastics GroupAcquisition United States
Pexco LLCUndisclosedThe new entity will feature multiple thermoplastic and silicone tubing extrusion, injection molding, film, packaging, and value-add manufacturing technologies across 20 plants, five countries, and three continents, comprising over 2,000 employeesPPC Industries, Inc.Merger United States
Vaxart, Inc.UndisclosedTo develop oral recombinant vaccines as tabletsCAS GroupMerger South Africa
Kerafast Inc.UndisclosedTo improving the selection of research tools available to the scientific community.Absolute Antibody Ltd.Merger United States
Corpus MedicalUndisclosedCombining Advanced Catheter Technology Design and Development with Confluent Medical Manufacturing CapabilitiesConfluent Medical TechnologiesAcquisition United States
IncoCare Gunhild Vieler GmbHUndisclosedTo further strengthen its position in Germany. Together, Coloplast and IncoCare will bring innovative products and services to more users across GermanyColoplastAcquisition Germany
Texas A&M University Health Science Center College of Medicine Institute for Regenerative MedicineUndisclosedThe Agreement for Alzheimer’s Research & Celltex acquires intellectual property license, signs multi-year research study with Texas A&M Health Science CenterCelltex Therapeutics CorporationLicense Acquisition & Research AgreementUnited States
NCPC GeneTech BiotechnologyUndisclosedTo export CJ-40001, a second-generation erythropoietin (EPO) biosimilarCJ HealthCareContract AgreementChina
SanofiUndisclosedTo develop, manufacture, and commercialize Leukine (sargramostim)Partner TherapeuticsAcquisition France
AmgenUndisclosedAgreement for the cholesterol-lowering drug, Repatha® (evolocumab)AbarcaOutcomes-Based Contract United States
Biohaven Pharmaceutical Holding CompanyUndisclosedTo provide Catalent’s Zydis® ODT (orally disintegrating tablet) fast-dissolving formulation for the development of Biohaven’s lead calcitonin gene-related peptide (CGRP) receptor antagonist product candidate, rimegepantCatalent U.K. Swindon Zydis LimitedExclusive Worldwide License AgreementUnited States
Health Elite Club Limited ("HECL")UndisclosedTo Distribute ZanthoSyn® in ChinaCardax, IncPurchase AgreementHong Kong
GC PharmaUndisclosedTo Develop and Commercialise GCC-4401C, an Investigational AnticoagulantLee's Pharmaceutical (HK) LimitedLicensing Agreement Republic of Korea
Shanghai Dahua Pharmaceutical Co.,Ltd.UndisclosedTo increase access to contraceptive implantsDKT InternationalAgreementChina
BC PlatformsUndisclosedIt will be using its technology solutions and research platform, including BCRQUEST.COM, to study data in cardiovascular diseasesPfizer FinlandPartnership Switzerland
MKO Global PartnersUndisclosedCompany expands presence in the pharma consulting space with the addition of pricing and payer strategy servicesTwo LabsPartnership United States
AstraZenecaUndisclosedImmuno Oncology Clinical Trial Collaboration & it will evaluate combination of SNDX-6352 with durvalumab (ImfinziTM) in solid tumorsSyndax Pharmaceuticals, Inc.CollaborationUnited Kingdom
Roivant SciencesUndisclosedA proposal to jointly develop Arbutus’ nucleic acid delivery platform based on its Lipid Nanoparticle (LNP) technology and GalNAc technology (collectively, Delivery Technologies) through a new company that would jointly own, manage, and develop the Delivery TechnologiesArbutus Biopharma CorporationAgreement Switzerland
Fujifilm CorporationUndisclosedTo develop regenerative medicine therapies using cardiomyocytes derived from iPSC for the treatment of heart failureTakeda Pharmaceutical CompanyCollaboration Japan
Arix Bioscience plcUndisclosedTo develop and commercialise innovative therapies.IpsenAgreementUnited Kingdom
SCD PharmaceuticalsUndisclosedTo develop, manufacture and market a portfolio of ophthalmic products in the U.S. and CanadaGlenmark PharmaceuticalsCollaboration AgreementUnited States
Kallyope IncUndisclosedTo Advance Programs Targeting the Gut-Brain AxisEuclidean Capital and Two Sigma VenturesSeries B Financing United States
Johnson & Johnson Services, IncUndisclosedTo establish a collaborative laboratory focused on 3D bioprintingAMBERCollaboration United States
Regulus TherapeuticsUndisclosedAgreement follows the recent opening of WuXi STA’s oligonucleotide R&D labs in China and the USAnWuXi & STACollaboration Agreement
Atomo DiagnosticsUndisclosedTo create next generation FebriDx® tests that are anticipated to transform the diagnosis of febrile acute respiratory infections (ARI) at the point-of-careRPS DiagnosticsPartnership Australia
Babraham Research Campus in Cambridge (UK)UndisclosedTo accelerate its AI-enabled drug developmentBenevolentAIAcquisition United Kingdom
AGC BiologicsUndisclosedTo continue development and advancement of CB 2679d through the clinicCatalyst BiosciencesManufacturing AgreementUnited States
Selexis SAUndisclosedTo Advance its Pipeline of XmAb Bispecific Antibody Drug CandidatesXencorExpanded Partnership Switzerland
BiosensorixUndisclosedTo Develop Next-Generation Point-of-Care Diagnostics Based on Research at Ben Gurion UniversityBGNTechnologiesCollaboration Singapore
BioventusUndisclosedTo Co-Develop Next Generation Bone AllograftLifeLink Tissue BankAgreement United States
LikardaUndisclosedTo offer online access to its innovative 3D compound screening and assay development services to scientists around the globe.Science ExchangePartnership United States
CiplaUndisclosedFor the promotion and sale of tocilizumab and the 2nd brand of bevacizumab (Avastin)Roche PharmaAgreementIndia
Aldeyra TherapeuticsUndisclosedTo Advance Novel Immune-Modulating Drugs for Systemic Inflammatory DiseasesJohnson & Johnson InnovationAgreement United States
ElektaUndisclosedTo continue development of clinical protocols for MR-linac technologyMemorial Sloan Kettering Cancer Center (MSK)Collaboration Sweden
JanssenUndisclosedFor access to TESARO's ZEJULA® (niraparib), an orally administered poly (ADP-ribose) polymerase (PARP) inhibitor undergoing clinical development, PARP inhibitor niraparib for Sierra's Phase 1b/2 combination trial with Chk1 inhibitor SRA737Sierra Oncology, Inc.Supply Agreement United States
Edico GenomeUndisclosedTo Streamline Clinical Next-Generation Sequencing WorkflowsInterSystemsPartnership United States
Kaken Pharmaceutical Co., LtdUndisclosedTo Develop And Commercialize New Chemical Entity For PsoriasisValeantLicensing Agreement Japan
Bavarian Nordic and AstraZenecaUndisclosedTo evaluate CV301 in combination with durvalumab in colorectal and pancreatic cancersGeorgetown University Dr. Michael PishvaianCollaboration Denmark
GenentechUndisclosedTo Evaluate Combination of ZEJULA® (Niraparib) and Anti-PD-L1 Cancer Immunotherapy in Metastatic Bladder CancerTESARO, Inc.Collaboration United States
NaveosUndisclosedAcquisition expands suite of revenue integrity solutions for healthcare providers and adds market-leading capabilities in government reimbursementRevint SolutionsAcquisition United States
MHM ServicesUndisclosedTo Expand National Footprint In Correctional Healthcare SectorCentene CorporationDefinitive Agreement
Acorda Therapeutics, IncUndisclosedDeveloping therapies which improve the lives of people with neurological disorders- Parkinson’s disease and multiple sclerosisScopia Capital ManagementCollaboration AgreementUnited States
Median TechnologiesUndisclosedMedian and CMIC will leverage complementary expertise to help biopharmaceutical companies accelerate oncology drug development in Japan, China and East Asia.CMIC HOLDINGS Co., Ltd.Collaboration AgreementUnited States
Tissue Regenix BioSurgeryUndisclosedCompanies collaborate to educate surgeons and hospitals about the safety, comfort and performance advantages of DermaPure® biologic for pelvic floor surgeryARMS MedicalDistribution AgreementUnited States
CellSystems GmbHUndisclosedFor AlphaSTEM™ Naïve Stem Cell Culture SystemMinerva BiotechnologiesDistribution AgreementGermany
Tolmar Australia Pty LimitedUndisclosedExclusive distribution rights for the oncology medication Eligard®Mundipharma Pty LimitedAcquisitionAustralia
Q Biomed IncUndisclosedFor a Novel Companion Biomarker for Monitoring Glaucoma , Under the agreement granting the exclusive right to license the technology,Washington University in St. LouisExclusive Option Agreement United States
Mindstrong HealthUndisclosedDevelopment of digital biomarkers for selected mental health conditionsTakeda Pharmaceutical Company LimitedPartnershipUnited States
ElsevierUndisclosedTo Enable Deeper Research into Traditional Chinese MedicineBeijing University of Chinese MedicineCollaborationUnited States
HOVONUndisclosedTo Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for ChemotherapyGlycoMimetics, IncAgreementNetherlands
MedidataUndisclosedTo include Edge eTMF and Edge CTMSAperio or iNNO Clinical Expansion AgreementUnited States
MAB Discovery GmbH (MABD)UndisclosedTo develop novel antibody therapeutics based on MABD’s unique discovery platformCullinan Oncology, LLCCollaboration Germany
OncoLensUndisclosedEnabling patients to enroll in trials faster, obtain treatment at local community cancer centersOptimal ResearchCollaboration United States
BullFrog AIUndisclosedTo Improve Antipsychotic Drug SelectionLieber Institute for Brain DevelopmentCollaboration United States
Charles RiverUndisclosedTo Accelerate Drug Discovery and DevelopmentHemaCarePartnershipUnited States